Premium
P2‐237: ASSOCIATION OF CSF ALPHA‐SYNUCLEIN AND TAU CONCENTRATIONS WITH AMYLOID MEAN CORTICAL STANDARD UPTAKE VALUE RATIOS IN PRECLINICAL SUBJECTIVE MEMORY COMPLAINERS STRATIFIED BY ALZHEIMER'S DISEASE BIOMARKERS
Author(s) -
Vergallo Andrea,
Bun René Sosata,
Toschi Nicola,
Baldacci Filippo,
Zetterberg Henrik,
Blennow Kaj,
Cavedo Enrica,
Lamari Foudil,
Habert Marie-Odile,
Dubois Bruno,
Floris Roberto,
Garaci Francesco,
Lista Simone,
Hampel Harald
Publication year - 2018
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2018.06.924
Subject(s) - cerebrospinal fluid , cohort , biomarker , medicine , asymptomatic , standardized uptake value , positron emission tomography , amyloid beta , amyloid (mycology) , disease , beta (programming language) , oncology , alpha synuclein , gastroenterology , pathology , nuclear medicine , parkinson's disease , chemistry , biochemistry , computer science , programming language
Background:There have been several human studies regarding sleep parameters and their potential relationship with Alzheimer’s disease (AD) pathogenesis. In this pilot study we investigated sleep architecture in subjective memory impairment (SMI), mild cognitive impairment (MCI), and AD patients who completed amyloid PET scans prior to assessment of their sleep architecture using WatchPAT which enables measurements of sleep parameters at home. We hypothesized that patients with AD spectrum disorders or subjects with amyloid pathology in the brain may have more sleep problems. Methods: From the FLORIAN study at Asan Medical Center, Seoul, Korea, a total of 45 subjects (AD, 16; MCI 17; normal cognition or SMI, 6; and other dementia, 6) were enrolled. The FLORIAN study, as shown on the poster presented by Dr. E Rhee, is an in-house cohort of AD spectrum disorders and other dementia, in which participants completed detailed neuropsychological tests, MRI, 18F-Florbetaben PET, and blood tests. Unexpectedly, around 30% of AD subjects failed to complete the WatchPAT monitoring and finally a total of 38 subjects (AD, 11; MCI 16; normal cognition or SMI, 6; other dementia, 5) completed the study. Quality and quantity of sleep and other sleep architectures were measured overnight by monitoring peripheral arterial tone signal reflecting the sympathetic nervous system activation. Results:MCI patients showed increase in light sleep time and AD patients slept less on supine position compared to normal control/ SMI subjects. When analyzed per amyloid imaging, subjects with amyloid positivity had a tendency to have delayed sleep latency compared to the amyloid negative group. Conclusions: This pilot study results suggest poor sleep quality in AD spectrum disorders or subjects with amyloid in the brain. Further studies with increased number of subjects and longitudinal follow-up will provide more information of the causal relationship between the sleep and AD pathogenesis.